A proof-of-concept clinical trial of BLU-554 in combination with CS1001 as a first-line treatment in patients with hepatocellular carcinoma in China
Phase of Trial: Phase II
Latest Information Update: 28 Jan 2019
At a glance
- Drugs BLU 554 (Primary) ; CS 1001 (Primary)
- Indications Liver cancer
- Focus Proof of concept; Therapeutic Use
- 28 Jan 2019 According to Blueprint Medicines media release, the National Medical Products Administration (NMPA) has approved the clinical trial application (CTA) to start this trial in China for BLU-554 (CS3008). The company expects to begin enrolment soon.
- 28 Jan 2019 Status changed from planning to recruiting, according to Blueprint Medicines media release.
- 04 Jan 2019 According to Blueprint Medicines media release, this trial is expected to initiate in the second half of 2019.